• Lundbeck banks on migraine therapy with $2bn acquisition

    Lundbeck is set to acquire Alder BioPharmaceuticals for a cash deal of $1.95bn (€1.77bn), with the latter company having readied its calcitonin …

    Read More
  • 0 0